Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
about
Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function.Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).Population pharmacokinetics of abacavir in plasma and cerebrospinal fluidMultiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosingPopulation pharmacokinetics of abacavir in pregnant women.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.Recent advances in the synthesis of the carbocyclic nucleosides as potential antiviral agents.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population pharmacokinetics of abacavir in infants, toddlers and children.Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugsSteady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers.Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.A model-based approach to dose selection in early pediatric development.Abacavir hypersensitivity reaction.Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.Synthesis of (+/-)-4'-ethynyl and 4'-cyano carbocyclic analogues of stavudine (d4T).
P2860
Q31975873-F5B7D647-586F-40C0-AA7F-6E2512DDB493Q33207117-1C01195B-4DC0-4609-B807-BF454BD6DF76Q33720839-48E392AA-1396-4570-B2AA-99366E6414A7Q33822912-62F1D9F3-070F-4D9C-957B-3D566644F6BBQ33836584-D8D15D37-094E-4DF9-AAF5-CAE637C8F937Q33980172-07339C28-3155-4F23-B487-25F95E4AACA3Q33981100-E83AE462-7568-4382-A7D9-6A883F47ED8BQ34299084-61EFDBBF-8EFC-434D-9A34-CFD410E70A6FQ35013781-CA4039A1-A4A4-4789-9A42-00DE6A607F35Q35233168-60F37F88-25E3-4B66-9AB9-2FE24BA7A930Q35826691-75D1D64C-8298-46D5-9EFC-7D9BAFE4A084Q35944285-C881305D-03B0-4581-A9EA-65368D35B221Q36036400-BCF58167-D536-4727-8DE9-57D3FD20E3ABQ36905884-133342D8-B174-43B6-9902-957788444680Q36948138-8E85DCA4-1B25-4A0B-A9E6-B4ED6A513694Q37018003-0219803B-9C90-4041-B89F-68B4B1CC2A30Q37144895-4955132C-9145-4307-B15B-B7FD76F82631Q37245017-DF666127-5EEA-41EA-AC1F-6E0C6A4F83C2Q37361807-065B4A27-7F59-473B-B596-ABB73D36C04CQ37399199-5AE24091-77ED-46D7-9F2A-DC1D634F6777Q37656345-EEDEF923-F681-423D-85C4-7BBEF93DD7BBQ42647571-08ABAB7C-9A2E-407B-9A5E-D3E95DD4399BQ43182469-5E95F9AB-3E10-4BEE-B726-200F8F2C4752Q43933908-0BE89ED6-66B7-46B2-9DFE-4F5AC6B14C3AQ45117171-D2BA91C3-E3E7-430B-BBE5-7554E34DD6ADQ46431512-4AD0693A-6532-44FC-9318-C3C2783A851C
P2860
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Population pharmacokinetics an ...... iency virus-infected subjects.
@ast
Population pharmacokinetics an ...... iency virus-infected subjects.
@en
type
label
Population pharmacokinetics an ...... iency virus-infected subjects.
@ast
Population pharmacokinetics an ...... iency virus-infected subjects.
@en
prefLabel
Population pharmacokinetics an ...... iency virus-infected subjects.
@ast
Population pharmacokinetics an ...... iency virus-infected subjects.
@en
P2093
P2860
P1476
Population pharmacokinetics an ...... iency virus-infected subjects.
@en
P2093
P2860
P304
P356
10.1128/AAC.44.8.2052-2060.2000
P407
P577
2000-08-01T00:00:00Z